Teva Pharmaceutical’s stock climbs as schizophrenia treatment shows promise

Teva Pharmaceutical Industries stock jumped more than 6% early Wednesday after the company reported first-quarter sales that topped estimates and released positive late-stage trial data on a schizophrenia treatment.